The impact of the COVID-19 surge after the end of China’s Zero-COVID policy on the health-related quality of life of IBD patients.

Publication date: Sep 16, 2024

In December 2019, COVID-19 emerged in Wuhan, Hubei Province, China, and rapidly spread worldwide. On December 2022, the Chinese government ended the zero-COVID policy, leading to a surge in cases and significantly impacting daily life. IBD patients face heightened infection risks and substantial effects on their quality of life during the pandemic. This cross-sectional study collected demographic, COVID-19-related, and HRQoL data from 224 IBD patients who had previously received treatment at Nanjing BenQ Medical Center. Participants completed an online survey between January 9, 2023, and January 23, 2023. The SIBDQ was used to assess HRQoL. Statistical analysis was performed using SPSS version 26. The study found that UC patients reported higher HRQoL compared to CD patients (p = 0. 037). Patients who perceived themselves as less susceptible to COVID-19 had higher scores (p = 0. 006 and p = 0. 009). Those whose work or study was unaffected also had higher scores (p < 0. 001 and p = 0. 002). Additionally, irregular medication adherence was associated with lower HRQoL scores (p = 0. 014 and p = 0. 007). Multivariate linear regression results showed that IBD patients whose work or study was affected during the COVID-19 pandemic scored lower than those who were not affected (p = 0. 038; 95% CI, -7. 96 to -0. 25). Patients who discontinued IBD medication scored higher than those with irregular medication use (p = 0. 020; 95% CI, 1. 00 to 10. 90). This study highlights the significant impact of the COVID-19 pandemic on the HRQoL of IBD patients. The findings emphasize the need for integrated care addressing both the physical and psychological aspects of IBD.

Open Access PDF

Concepts Keywords
China Adult
December China
Pandemic COVID-19
Unaffected COVID-19
Cross-Sectional Studies
Cross-sectional survey
Female
Health Policy
Humans
Inflammatory bowel disease
Inflammatory Bowel Diseases
Male
Medication Adherence
Middle Aged
Quality of Life
SARS-CoV-2
Surveys and Questionnaires
Young Adult

Semantics

Type Source Name
disease MESH COVID-19
disease IDO quality
disease MESH infection
pathway REACTOME Reproduction
drug DRUGBANK Troleandomycin
disease MESH Inflammatory bowel disease
pathway KEGG Inflammatory bowel disease
drug DRUGBANK Coenzyme M
disease IDO production
disease MESH anxiety
disease MESH privacy
disease IDO nucleic acid
drug DRUGBANK Tocilizumab
disease MESH mental illness
drug DRUGBANK Trestolone
disease MESH ulcerative colitis
drug DRUGBANK Mesalazine
disease IDO symptom
disease IDO history
disease MESH complications
disease IDO susceptibility
drug DRUGBANK Acetylsalicylic acid
drug DRUGBANK Azathioprine
drug DRUGBANK Methotrexate
drug DRUGBANK Adalimumab
drug DRUGBANK Infliximab
disease MESH Conjunctivitis
disease MESH chronic diseases
disease MESH psychological stress

Original Article

(Visited 1 times, 1 visits today)